Drag a card by its title · ⚙ to size, swap or remove

The company

Taysha Gene Therapies, Inc.

TSHA · Nasdaq

Health CareBiotechnologyNot moving yet

TSHA stood above a rising 150-day average in 42 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 35.3% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 6
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $11.6M
Officials’ trades on record: 0
Institutions holding: 201 (+18)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 42 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months12

Buyers · sellers0 · 3

Who	Did	Shares	Traded
Sukumar NagendranPresident and Head of R&D	sold	200,000at $6.24	10 Jul 2026filed 10 Jul 2026
Sukumar NagendranPresident and Head of R&D	sold	200,000at $4.46	10 Apr 2026filed 13 Apr 2026
Kamran AlamCHIEF FINANCIAL OFFICER	sold	1,655at $4.52	4 Feb 2026filed 6 Feb 2026
Sean P. NolanChief Executive Officer	sold	41,312at $4.61	26 Jan 2026filed 27 Jan 2026
Sukumar NagendranPresident and Head of R&D	sold	26,918at $4.61	26 Jan 2026filed 27 Jan 2026
Kamran AlamCHIEF FINANCIAL OFFICER	sold	23,849at $4.61	26 Jan 2026filed 27 Jan 2026
Sean P. NolanChief Executive Officer	sold	136,789at $4.75	23 Jan 2026filed 27 Jan 2026
Sukumar NagendranPresident and Head of R&D	sold	89,132at $4.75	23 Jan 2026filed 27 Jan 2026
Kamran AlamCHIEF FINANCIAL OFFICER	sold	78,968at $4.75	23 Jan 2026filed 27 Jan 2026
Sukumar NagendranPresident and Head of R&D	sold	200,000at $4.71	12 Jan 2026filed 14 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders201+18 on the quarter

New · exited41 · 23

Reported value$2.1B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
Avoro Capital Advisors LLCadded · filed 14 Aug 2026	23,888,888$162.7M	+2,188,888+10.1%
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 2026	23,555,648$160.4M	00.0%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026	22,713,118$154.7M	+343,473+1.5%
BlackRock, Inc.added · filed 7 Aug 2026	20,691,927$140.9M	+2,326,319+12.7%
Vestal Point Capital, LPadded · filed 14 Aug 2026	19,415,000$132.2M	+1,415,000+7.9%
MORGAN STANLEYreduced · filed 13 Aug 2026	16,487,479$112.3M	-1,477,892−8.2%
RTW INVESTMENTS, LPreduced · filed 14 Aug 2026	13,560,258$92.3M	-119,990−0.9%
FMR LLCreduced · filed 13 Aug 2026	13,336,413$90.8M	-984,842−6.9%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	12,478,595$85.0M	+2,247,093+22.0%
STATE STREET CORPadded · filed 7 Aug 2026	11,421,920$77.8M	+212,842+1.9%